MannKind reported $16.14M in Trade Creditors for its fiscal quarter ending in March of 2026.





Trade Creditors Change Date
Adma Biologics USD 20.52M 2M Mar/2026
BioCryst Pharmaceuticals USD 10.96M 4.87M Mar/2026
Eli Lilly USD 5.03B 350M Mar/2026
Halozyme Therapeutics USD 14.1M 6.8M Mar/2026
Insmed USD 73.38M 6.53M Mar/2026
Karyopharm Therapeutics USD 4M 1.39M Dec/2025
MacroGenics USD 4.29M 500K Mar/2026
MannKind USD 16.14M 7.11M Mar/2026
Merck USD 3.86B 541M Mar/2026
Minerva Neurosciences USD 640K 305K Dec/2025
Novavax USD 16.1M 8.48M Mar/2026
Novo Nordisk DKK 4.46B 15.12B Jun/2025
Pfizer USD 4.51B 734M Mar/2026
Sanofi EUR 22.71B 219M Mar/2026
Xencor USD 7.92M 2.91M Mar/2026